Strategies to increase access to basic sickle cell disease care in low- and middle-income countries

Dua, Meghna; Bello‐Manga, Halima; Carroll, Yvonne; Galadanci, Aisha Amal; Ibrahim, Umma A.; King, Allison A.; Olanrewaju, Ayobami; Estepp, Jeremie H.

doi:10.1080/17474086.2022.2063116

Cited by 11 publications

(8 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in adult patients with SCD presenting with acute ischemic stroke who otherwise meet eligibility criteria, IV thrombolysis is suggested but should not delay blood transfusion therapy 1 . In addition to following evidence-based guidelines for the management of SCD, there is also a dire need to improve access to neurologic and hematologic care for affected populations 5-7,14 …”

Section: Sickle Cell Diseasementioning

confidence: 99%

“…3,4 Worldwide, SCD affects approximately 20 to 25 million people, with the majority living in sub-Saharan Africa. [5][6][7] SCD can affect the central nervous system through a spectrum of neurovascular injuries including stroke, seizure, headache, and neurocognitive impairment (CASE 6-1). 3,8 People with SCD are 2 to 3 times more likely to develop epilepsy than the general population.…”

Section: Sickle Cell Diseasementioning

confidence: 99%

“…1 In addition to following evidence-based guidelines for the management of SCD, there is also a dire need to improve access to neurologic and hematologic care for affected populations. [5][6][7]14 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder of hematopoietic stem cells caused by a mutation in the X-linked phosphatidylinositol glycan class A ( PIGA) gene that affects complement binding on blood cells and may lead to hemolytic anemia, bone marrow failure, and an increased risk of thrombosis. [18][19][20] Venous thromboembolism, including cerebral venous sinus thrombosis, is a common cause of morbidity and mortality in patients with PNH, but arterial thrombotic events, including ischemic stroke, may also occur.…”

Section: Commentmentioning

confidence: 99%

“…In the United States, approximately 1 in 365 African American people has SCD and about one in 13 African American people has a heterozygous sickle cell trait 3,4 . Worldwide, SCD affects approximately 20 to 25 million people, with the majority living in sub-Saharan Africa 5-7 …”

Section: Sickle Cell Diseasementioning

confidence: 99%

See 3 more Smart Citations

Hematologic Disorders and the Nervous System

Mauermann¹,

Southerland²

2023

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

OBJECTIVE This article discusses the epidemiology, diagnosis, treatment, and prevention of neurologic complications of red blood cell, platelet, and plasma cell disorders. LATEST DEVELOPMENTS Cerebrovascular complications can occur in patients with blood cell and platelet disorders. Treatment strategies to prevent stroke are available for patients with sickle cell disease, polycythemia vera, and essential thrombocythemia. A diagnosis of thrombotic thrombocytopenic purpura should be considered in patients with neurologic symptoms, hemolytic anemia, thrombocytopenia, mild renal insufficiency, and fever. Plasma cell disorders can be associated with peripheral neuropathy, and classification of the monoclonal protein type and neuropathy aid in diagnosis. Patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) syndrome can present with arterial and venous neurologic events. ESSENTIAL POINTS This article discusses the neurologic complications of blood cell disorders and the most recent advances in prevention and treatment.

show abstract

Section: Sickle Cell Diseasementioning

confidence: 99%

Section: Sickle Cell Diseasementioning

confidence: 99%

Section: Commentmentioning

confidence: 99%

Section: Sickle Cell Diseasementioning

confidence: 99%

See 2 more Smart Citations

Hematologic Disorders and the Nervous System

Mauermann¹,

Southerland²

2023

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

show abstract

“…Given the widespread and complex mechanism of action, crizanlizumab may have applications beyond the realm of sickle cell disease [22][23][24]. COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin.…”

Section: Crizanlizumabmentioning

confidence: 99%

Novel Strategies for the Treatment of COVID-19

McCarthy

2022

Drugs R D

View full text Add to dashboard Cite

On 4 September, 2020, the US National Institutes of Health launched a new clinical trial, “A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults with COVID-19.” This open-label, placebo-controlled, multicenter, adaptive platform study was designed to evaluate therapeutic options for patients hospitalized with mild, moderate, or severe COVID-19. A variety of drugs and drug classes were selected, including heparin, the monoclonal antibody crizanlizumab, sodium-glucose cotransporter-2 inhibitors, and purinergic signaling receptor Y 12 inhibitors. These medications have been widely used in the treatment of other conditions, from sick cell disease to type 2 diabetes mellitus and some forms of cardiovascular disease, but their inclusion in a study of COVID-19 was somewhat unexpected. This article examines the rationale behind the use of these disparate agents in the treatment and prevention of adverse outcomes in patients with COVID-19 and explores how these strategies may be utilized in the future to address the severe acute respiratory syndrome coronavirus 2 pandemic.

show abstract